CN111278443A - 使用rhoa显性负型治疗癌症的组合物和方法 - Google Patents

使用rhoa显性负型治疗癌症的组合物和方法 Download PDF

Info

Publication number
CN111278443A
CN111278443A CN201880066812.2A CN201880066812A CN111278443A CN 111278443 A CN111278443 A CN 111278443A CN 201880066812 A CN201880066812 A CN 201880066812A CN 111278443 A CN111278443 A CN 111278443A
Authority
CN
China
Prior art keywords
cancer
rhoa
cells
dominant
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880066812.2A
Other languages
English (en)
Chinese (zh)
Inventor
A·巴斯
H·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CN111278443A publication Critical patent/CN111278443A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880066812.2A 2017-11-08 2018-11-05 使用rhoa显性负型治疗癌症的组合物和方法 Pending CN111278443A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762583166P 2017-11-08 2017-11-08
US62/583,166 2017-11-08
PCT/US2018/059188 WO2019094326A1 (en) 2017-11-08 2018-11-05 Compositions and methods for treating cancer using rhoa dominant negative forms

Publications (1)

Publication Number Publication Date
CN111278443A true CN111278443A (zh) 2020-06-12

Family

ID=66439269

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880066812.2A Pending CN111278443A (zh) 2017-11-08 2018-11-05 使用rhoa显性负型治疗癌症的组合物和方法

Country Status (7)

Country Link
US (1) US11957739B2 (https=)
EP (1) EP3706751A4 (https=)
JP (1) JP2021502329A (https=)
CN (1) CN111278443A (https=)
AU (1) AU2018365800A1 (https=)
CA (1) CA3076269A1 (https=)
WO (1) WO2019094326A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957739B2 (en) 2017-11-08 2024-04-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer using RHOA dominant negative forms
SE2000055A1 (sv) * 2020-03-15 2021-09-16 Martin Ivanov Denev Användande av fotohydrauliskt mekanisk chock, för selektiv sprängning av relativ svagare cellmembranen av cancerceller, vilka har svagare cellmembran än friska celler
CN113278706B (zh) * 2021-07-23 2021-11-12 广州燃石医学检验所有限公司 一种用于区分体细胞突变和种系突变的方法
WO2024059823A1 (en) * 2022-09-15 2024-03-21 Iview Therapeutics, Inc. Self-complementary AAV vectors carrying dominant negative RhoA and methods of use to treat ocular diseases

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208862A1 (en) * 2001-10-12 2004-10-21 Case Western Reserve University Neuronal regeneration
US20060105374A1 (en) * 2004-11-12 2006-05-18 Sebti Said M RhoB variants and methods of use
US20070048750A1 (en) * 2005-09-01 2007-03-01 National Health Research Institute Rapid efficacy assessment method for lung cancer therapy
US20070161060A1 (en) * 2005-09-07 2007-07-12 Anderson Richard A Screening method for identifying an agent that modulates PIPKIgamma trafficking of E-cadherin
WO2009076966A2 (en) * 2007-12-19 2009-06-25 Rhovac Aps Rhoc-based immunotherapy
CN102144163A (zh) * 2008-04-10 2011-08-03 麻省理工学院 关于鉴定和使用靶向癌症干细胞的试剂的方法
CN103596974A (zh) * 2011-04-15 2014-02-19 卡姆普根有限公司 多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1274463A2 (en) * 1999-12-10 2003-01-15 Whitehead Institute For Biomedical Research Metastasis genes and uses thereof
WO2005072141A2 (en) * 2004-01-16 2005-08-11 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of rhoa signaling
WO2009089040A1 (en) * 2008-01-11 2009-07-16 Jaffrey Samie R Methods for expressing proteins in axons
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US11957739B2 (en) 2017-11-08 2024-04-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer using RHOA dominant negative forms

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208862A1 (en) * 2001-10-12 2004-10-21 Case Western Reserve University Neuronal regeneration
US20060105374A1 (en) * 2004-11-12 2006-05-18 Sebti Said M RhoB variants and methods of use
US20070048750A1 (en) * 2005-09-01 2007-03-01 National Health Research Institute Rapid efficacy assessment method for lung cancer therapy
US20070161060A1 (en) * 2005-09-07 2007-07-12 Anderson Richard A Screening method for identifying an agent that modulates PIPKIgamma trafficking of E-cadherin
WO2009076966A2 (en) * 2007-12-19 2009-06-25 Rhovac Aps Rhoc-based immunotherapy
CN102144163A (zh) * 2008-04-10 2011-08-03 麻省理工学院 关于鉴定和使用靶向癌症干细胞的试剂的方法
CN103596974A (zh) * 2011-04-15 2014-02-19 卡姆普根有限公司 多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
孙晓杰: "《肿瘤分子诊断与靶向治疗》", 31 July 2009, 第二军医大学出版社 *
樊代明: "《肿瘤研究前沿 第2卷》", 31 December 2002, 西安交通大学出版社 *
樊代明: "《肿瘤研究前沿 第3卷》", 31 December 2003, 西安交通大学出版社 *
陈临溪 等: "《细胞信号转导药理与临床》", 31 October 2014, 人民军医出版社 *

Also Published As

Publication number Publication date
US11957739B2 (en) 2024-04-16
AU2018365800A1 (en) 2020-04-02
EP3706751A1 (en) 2020-09-16
US20200261550A1 (en) 2020-08-20
JP2021502329A (ja) 2021-01-28
CA3076269A1 (en) 2019-05-16
EP3706751A4 (en) 2021-08-18
WO2019094326A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
CN109689062B (zh) 使用抗PI3Kβ和抗免疫检查点药剂的组合治疗PTEN缺陷型上皮癌的方法
EP3229837B1 (en) Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
AU2015206603B9 (en) Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
AU2015328411B2 (en) Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
US11740242B2 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
US11957739B2 (en) Compositions and methods for treating cancer using RHOA dominant negative forms
WO2018148378A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
WO2015077414A1 (en) Kynurenine pathway biomarkers predictive of anti-immune checkpoint inhibitor response
CN111148518A (zh) 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
EP3215845A1 (en) Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
US20200149042A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
AU2019227641B2 (en) Methods for treating cancer using combinations of anti-BTNL2 and immune checkpoint blockade agents
US20220288051A1 (en) Methods for treating cancer using serial administration of e3 ubiquitin ligase degraders
US20220289854A1 (en) Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
JP4025645B2 (ja) Ｐｉｂｆ濃度測定によるガン患者の検査方法
US20240024474A1 (en) Personalized fusion cell vaccines
HK40006303B (en) Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents
HK40006303A (en) Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents
CN107604064A (zh) Ccl20在肿瘤化疗疗效评估和肿瘤治疗中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200612